Abstract
Cell-based therapy holds great promise for cancer treatment. The ability to non-invasively track the delivery of various therapeutic cells (e.g. T cells and stem cells) to the tumor site, and/or subsequent differentiation/proliferation of these cells, would allow better understanding of the mechanisms of cancer development and intervention. This brief review will summarize the various methods for non-invasive cell tracking in cancer and cancer therapy. In general, there are two approaches for cell tracking: direct (cells are labeled with certain tags that can be detected directly with suitable imaging equipment) and indirect cell labeling (which typically uses reporter genes approach). The techniques for tracking various cell types (e.g. immune cells, stem cells, and cancer cells) in cancer are described, which include fluorescence, bioluminescence, positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Non-invasive tracking of immune and stem cells were primarily intended for (potential) cancer therapy applications while tracking of cancer cells could further our understanding of cancer development and tumor metastasis. Safety is a major concern for future clinical applications and the ideal imaging modality for tracking therapeutic cells in cancer patients requires the imaging tags to be non-toxic, biocompatible, and highly specific. Each imaging modality has its advantages and disadvantages and they are more complementary than competitive. MRI, radionuclide-based imaging techniques, and reporter gene-based approaches will each have their own niches towards the same ultimate goal: personalized medicine for cancer patients.
Keywords: Cancer, cell tracking, cancer therapy, stem cells, positron emission tomography, molecular imaging, optical imaging, magnetic resonance imaging
Current Topics in Medicinal Chemistry
Title: Non-Invasive Cell Tracking in Cancer and Cancer Therapy
Volume: 10 Issue: 12
Author(s): Hao Hong, Yunan Yang, Yin Zhang and Weibo Cai
Affiliation:
Keywords: Cancer, cell tracking, cancer therapy, stem cells, positron emission tomography, molecular imaging, optical imaging, magnetic resonance imaging
Abstract: Cell-based therapy holds great promise for cancer treatment. The ability to non-invasively track the delivery of various therapeutic cells (e.g. T cells and stem cells) to the tumor site, and/or subsequent differentiation/proliferation of these cells, would allow better understanding of the mechanisms of cancer development and intervention. This brief review will summarize the various methods for non-invasive cell tracking in cancer and cancer therapy. In general, there are two approaches for cell tracking: direct (cells are labeled with certain tags that can be detected directly with suitable imaging equipment) and indirect cell labeling (which typically uses reporter genes approach). The techniques for tracking various cell types (e.g. immune cells, stem cells, and cancer cells) in cancer are described, which include fluorescence, bioluminescence, positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Non-invasive tracking of immune and stem cells were primarily intended for (potential) cancer therapy applications while tracking of cancer cells could further our understanding of cancer development and tumor metastasis. Safety is a major concern for future clinical applications and the ideal imaging modality for tracking therapeutic cells in cancer patients requires the imaging tags to be non-toxic, biocompatible, and highly specific. Each imaging modality has its advantages and disadvantages and they are more complementary than competitive. MRI, radionuclide-based imaging techniques, and reporter gene-based approaches will each have their own niches towards the same ultimate goal: personalized medicine for cancer patients.
Export Options
About this article
Cite this article as:
Hong Hao, Yang Yunan, Zhang Yin and Cai Weibo, Non-Invasive Cell Tracking in Cancer and Cancer Therapy, Current Topics in Medicinal Chemistry 2010; 10 (12) . https://dx.doi.org/10.2174/156802610791384234
DOI https://dx.doi.org/10.2174/156802610791384234 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Human Neural Stem and Progenitor Cells: In Vitro and In Vivo Properties, and Potential for Gene Therapy and Cell Replacement in the CNS
Current Gene Therapy Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Activity Based Chemical Proteomics: Profiling Proteases as Drug Targets
Current Drug Discovery Technologies Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Analysis of Microarray Gene Expression Data
Current Bioinformatics Activatable Optical Probes for the Detection of Enzymes
Current Organic Synthesis Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)
Current Pharmacogenomics and Personalized Medicine Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders
Current Pharmaceutical Design Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets